TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: V260 Registration Study (V260-013)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At first study vaccination, age 6 weeks through exactly 12 weeks~Exclusion Criteria:~* History of congenital abdominal disorders, intussusception, or abdominal surgery~* History of known prior rotavirus disease~* Ongoing chronic diarrhea or failure to thrive~* Clinical evidence of active gastrointestinal illness

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 12 Weeks
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): RotaTeq
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Varying Proportions of Low and High Energy Dense Foods Over 5 Days in Preschool Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Attending one of the designated daycare centers~Exclusion Criteria:~* Food Allergies~* Food restrictions~* Health Issues that Preclude Participation~* Not available for duration of the study

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: EXPERIMENTAL): Baseline proportions of high and low energy dense foods.
- Addition (Type: EXPERIMENTAL): Increased portion of low energy dense foods.
- Substitution (Type: EXPERIMENTAL): Increased portion of low energy dense foods substituted for equal portion of foods higher in energy density.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Adjunctive Rosiglitazone in the Treatment of Uncomplicated Falciparum Malaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Microscopically confirmed P.falciparum infection~* Age \>18 years~* Able to tolerate oral therapy~* Able to give informed consent~Exclusion Criteria:~* Fulfillment of WHO criteria for severe/cerebral malaria~* Prior treatment with any thiazolidinedione~* Allergy to rosiglitazone~* History of diabetes mellitus~* History of severe/decompensated liver disease~* ALT level \>2.5 times normal~* Current treatment for congestive heart failure~* Pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 2 (Type: PLACEBO_COMPARATOR): None
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Tolerability of Tauroursodeoxycholic Acid in Amyotrophic Lateral Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Caucasian male or female out-patients;~* aged 18 to 75 years inclusive;~* diagnosis of probable or definite amyotrophic lateral sclerosis according to the El Escorial revised criteria (1);~* first symptoms of ALS by no more than 1.5 years;~* in treatment with steady regimen of riluzole for a minimum of 3 months before study entry, and desiring its continuation;~* FVC ≥ 75% of predicted;~* no conditions known to be contraindications to the use of TUDCA;~* written informed consent.~Exclusion Criteria:~* subjects who underwent tracheostomy;~* subjects who underwent resection of gall bladder;~* subjects with signs of conduction blocks of motor nerves, sensory nerves or both on nerve conduction study;~* subjects with clinical signs of dementia;~* subjects with active peptic ulcer;~* subjects with active malignancy;~* subjects with bulbar onset;~* female subjects who are pregnant or lactating~* subjects who have received an experimental drug or have participated in a clinical trial within 3 months prior to screening~* employees of the investigator or study centre with direct involvement in the proposed study or other studies under the direction of that investigator or study centre.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- TUDCA (Type: EXPERIMENTAL): tauroursodeoxycholic acid di-hydrate
- placebo (Type: PLACEBO_COMPARATOR): excipient lactose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Type 1 Diabetes mellitus (T1DM)~* Central laboratory C-peptide \< 0.7 ng/ml (0.23 nmol/L)~* Insulin use for at least 12 months per patient reported or medical records~* Method of insulin administration (MDI or CSII) must have been unchanged for at least 3 months prior to screening~* Subjects must be on a total insulin dose of ≥ 0.3 U/kg/day for at least 3 months prior to screening~* If on MDI insulin administration, subject must be on ≥ 3x injections per day~* Screening Visit: Central laboratory HbA1c ≥ 7.7% and ≤ 11.0%~* Body mass index (BMI) ≥ 18.5 kg/m2~Exclusion Criteria:~* History of Type 2 Diabetes mellitus (T2DM) or maturity onset diabetes of the young (MODY), pancreatic surgery, or chronic pancreatitis that could result in decreased beta cell capacity~* Taking any non-insulin antihyperglicemic agent within 1 month prior to screening~* Taking GLP-1 receptor agonist within 2 months prior to screening for once weekly administration and within 1 month prior to screening for once or twice daily administration~* Taking metformin and/or thiazolidinediones within 2 months prior to screening~* History of diabetes ketoacidosis requiring medical intervention within 1 month prior to screening~* History of hospital admission for glycemic control (either hyperglycemia or hypoglycemia) within 1 month prior to screening~* Frequent episodes of severe hypoglycemia (more than one episode requiring medical assistance, emergency care), and/or glucagon therapy administered by a third-party individual within 1 month prior to screening~* History of Addison's disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Dapagliflozin 5 mg (Type: EXPERIMENTAL): Dapagliflozin 5 mg tablet orally, once daily for 52 weeks
- Dapagliflozin 10 mg (Type: EXPERIMENTAL): Dapagliflozin 10 mg tablet orally, once daily for 52 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablet orally, once daily for 52 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Inhibition of Lipid Peroxidation During Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects, 18 to 80 years of age, scheduled for elective cardiac surgery requiring CPB~2. For female subjects, the following conditions must be met:~postmenopausal for at least 1 year, or status-post surgical sterilization, or if of childbearing potential, utilizing adequate birth control and a negative urine beta-hcg prior to drug treatment~Exclusion Criteria:~1. Allergic reaction to ApAP (acetaminophen)~2. Evidence of severe hepatic impairment (history of liver cirrhosis or total bilirubin \>2.0mg/dl)~3. Impaired renal function (serum creatinine \>2.0 mg/dl)~4. Emergency surgery~5. Pregnancy~6. Breast-feeding~7. Any underlying or acute disease requiring regular medication which could possibly pose a threat to the subject or make implementation of the protocol or interpretation of the study results difficult~8. History of alcohol or drug abuse~9. Treatment with any investigational drug in the 1 month preceding the study~10. Mental conditions rendering the subject unable to understand the nature, scope and possible consequences of the study~11. Inability to comply with the protocol, e.g. uncooperative attitude and unlikelihood of completing the study~12. History or evidence of active asthma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Acetaminophen (Type: ACTIVE_COMPARATOR): Acetaminophen will ge given as 1g every 6 hours for 4 doses over a 24 hours study period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Ocular Penetration of Topically Administered Fluoroquinolones

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who have a visually significant cataract and are planning to have cataract surgery.~* Subjects who are willing/able and have signed informed consent approved by the Institutional Review Board.~Exclusion Criteria:~* Subjects who have a known hypersensitivity, allergy, or contraindication to any fluoroquinolone medication, in any form.~* Subjects who signs of ocular infection or active inflammation in the study eye.~* Subjects who have corneal pathology, including epithelial defect, corneal scarring, or severe dry eye syndrome.~* Subjects who have used any disallowed medication (including antibiotics) during the time period designated as described in the protocol.~* Subjects who have any active or chronic/recurrent ocular or systemic disease that is uncontrolled and is likely to increase the risk of infection to the patient or confound the results of the study.~* Subjects who are pregnant (or suspect to be pregnant) or nursing/lactating.~* Subjects who have participated in any study of an investigational drug or device within 30 days prior to enrollment.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Moxifloxacin 0.5% ophthalmic solution (Type: ACTIVE_COMPARATOR): None
- Besifloxacin 0.6% ophthalmic suspension (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The FIGHT-RP1 Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~All subjects must meet the following criteria to be eligible for study entry:~* Signed informed consent and authorization of use and disclosure of protected health information~* Age \>18 years~* Patients diagnosed with RP by the investigators, based on clinical phenotype and diagnostic tests~Exclusion Criteria:~Subjects who meet any of the following criteria will be ineligible for study entry:~* Patients with concurrent retinal pathologies that result in vision loss, including but not limited to retinal vein occlusion, diabetic retinopathy and neovascular age-related macular degeneration. If one eye does not have any retinal pathology other than RP, it may be enrolled in the study.~* Patients with uncontrolled arterial hypertension defined as diastolic blood pressure \> 95 mm Hg or systolic blood pressure \> 160 mm Hg despite medical therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental Arm (carbonyl content >0.6, GSH/GSSG <3) (Type: EXPERIMENTAL): Subjects with RP will be enrolled in the experimental arm if they have a high carbonyl content (\>0.6) and a reduced GSH/GSSG ratio (\<3.0) in the aqueous.
- Exploratory Arm (carbonyl content <0.6, GSH/GSSG >3) (Type: EXPERIMENTAL): Subjects with RP who don't have a high carbonyl content (\>0.6) and a reduced GSH/GSSG ratio (\<3.0) but otherwise are good candidates for the study will be enrolled in the exploratory arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has moderate to severe chronic noncancer pain (duration of at least 3 months) requiring a continuous around-the-clock opioid analgesic for an extended period of time. Conditions may include, but are not limited to, osteoarthritis, chronic low back pain, or other opioid -responsive pain conditions.~* Subject agrees to refrain from taking opioid medications other than study drug during the study. (The exception is during the Pre-Treatment Period when the subject may continue current opioid therapy to guide first 4 weeks of the Treatment Period when the subject may administer immediate-release oxycodone to support conversion to study drug.)~Exclusion Criteria:~* Subject has moderate or severe chronic pain due to cancer, migraine, recent trauma, infection, or other pain expected to be short-term (duration less than 3 months).~* Subject has a documented history of alcohol or drug abuse within 1 year prior to study entry that in the Investigator's judgment would impact subject participation.~* Subject has ongoing or active alcohol or drug abuse that in the Investigator's judgment would impact subject participation.~* Subject has a positive urine drug test for illicit drug use or medications at screening without legitimate medical explanation.~* Subject has a clinically significant medical condition (e.g., cardiovascular, neurological, renal, hepatic, pulmonary, gastrointestinal, endocrine, hematological, immunological, rheumatological, metabolic, or psychiatric) or physical examination, vital signs (VS), 12-lead electrocardiogram (ECG), clinical laboratory abnormalities that in the opinion of the Investigator would impact the safety of the subject during study participation.~* If female, the subject is pregnant or breast-feeding.~* Subject has a known history or known hypersensitivity to oxycodone, oxycodone salts, naltrexone or acetaminophen,or pharmacological similar compounds.~* Subject is historically non-responsive to oxycodone treatment or requires greater than 160 mg oxycodone in a 24-hour time interval.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- oxycodone HCl and naltrexone HCl extended-release capsules (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy infant able to attend all study visits~* Parent(s)/legal representative are able to read, understand, and complete study questionnaires~Exclusion Criteria:~* History of congenital or acquired immunodeficiency~* Received or is expected to receive immunosuppressive agents or systemic immunomodulatory steroids~* History of leukemia, lymphoma, malignant melanoma, or myeloproliferative disorder~* Hypersensitivity to any of the vaccine components or history of a life-threatening reaction to a vaccine containing the same substances as the study vaccines or concomitant study vaccines~* Has any chronic illness that could interfere with study conduct or completion~* Received any immune globulin, blood, or blood-derived products since birth~* Received a dose of hepatitis B vaccine prior to study entry~* Vaccinated with any acellular pertussis or whole cell pertussis based combination vaccines, Haemophilus influenzae type b conjugate, poliovirus, pneumococcal conjugate or pneumococcal polysaccharide, rotavirus vaccine, or combination thereof~* Fever within 24 hours prior to enrollment~* Received any non-study vaccine within 30 days prior to enrollment, except for inactivated influenza vaccine, which is permitted 14 days or more prior to enrolment~* Has a coagulation disorder~* Has developmental delay or neurological disorder~* Participant or his/her mother has a medical history of hepatitis B surface antigens (HBsAg) seropositivity~* History of Haemophilus influenzae type b, hepatitis B, diphtheria, tetanus, pertussis, poliomyelitis, rotavirus gastroenteritis, or invasive pneumococcal infection

- Gender: ALL
- Minimum Age: 46 Days
- Maximum Age: 89 Days
- Healthy Volunteers: t

Study Arms:
- PR5I (Type: EXPERIMENTAL): Infant series: PR5I 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 2 and 4 months of age, and rotavirus vaccine (either Rotarix™ 1.5 mL oral dose at 2 and 4 months of age \[subset 1\] or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age \[subset 2\]).~Toddler dose: PR5I 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 11 to 12 months of age.
- INFANRIX™ hexa (Type: ACTIVE_COMPARATOR): Infant series: INFANRIX™ hexa 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 2 and 4 months of age, and rotavirus vaccine (either Rotarix™ 1.5 mL oral dose at 2 and 4 months of age \[subset 1\] or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age \[subset 2\]).~Toddler dose: INFANRIX™ hexa 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 11 to 12 months of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women, 18 years of age or older.~* Subjects with Chronic Phase Ph+ CML.~* Subjects have not been treated with imatinib at a dose \>600 mg/day.~* Subjects developed resistance to disease while receiving an imatinib dose 400-600 mg/day.~* Able to tolerate imatinib at the highest dose the subject had received in the past.~* Demonstrate adequate renal and hepatic function.~* Women of childbearing potential must have a negative serum or urine pregnancy test, must be using an adequate method of contraception.~Exclusion Criteria:~* Women who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period for a least 1 month before and at least 3 months after the completion of the study.~* Women using a prohibited contraceptive method.~* Women who are pregnant or breastfeeding.~* Men whose sexual partners are women who are of childbearing potential, and who are unwilling or unable to use an acceptable method to avoid pregnancy of his partner for the entire study period as outlined above.~* Prior treatment with imatinib at a dose \>600 mg/day.~* Subjects who have previously identified specific BCR-ABL mutations.~* Previous diagnosis of accelerated phase or blast crisis CML.~* Intolerance to imatinib at any dose.~* Subjects who are eligible and willing to undergo transplantation during the screening period.~* Serious uncontrolled medical disorder or active infection.~* Uncontrolled or significant cardiovascular disease.~* Uncontrolled hypertension.~* Dementia or altered mental status.~* Evidence of organ dysfunction.~* Use of imatinib within 7 days.~* Use of interferon or cytarabine within 14 days.~* Use of a targeted small molecule anticancer agent within 14 days.~* Subjects taking certain medications that are accepted to have a risk of causing Torsades de Pointes.~* Subjects taking medications that irreversibly inhibit platelet function or anticoagulants.~* Prior therapy with BMS-354825.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Active Comparator
- 2 (Type: EXPERIMENTAL): Active Comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Heart Failure Center Program on Cardiac Outcomes in Patients With Heart Failure

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. patients hospitalized due to acute cardiogenic pulmonary edema documented on chest x-ray and~2. left ventricular ejection fraction (LVEF) \< 40% as documented by echocardiography; and~3. aged \> 20 and \< 80 years.~Exclusion Criteria:~1. the presence of systemic diseases such as hypothyroidism, decompensated liver cirrhosis, and systemic lupus erythematosus;~2. a disorder other than HF that might compromise survival within 6 months;~3. having implanted materials that could interfere with the bioimpedance analysis,~4. being bed-ridden for \> 3 months and/or unable to stand alone;~5. having serum creatinine of \> 5 mg/dl or nephritic syndrome;~6. having active cellulites, severe varicose veins, lymphedema or deep vein thrombosis over lower extremity;~7. undergoing dialysis within 2 weeks;~8. having severe coronary artery disease without complete revascularization therapy; and~9. being pregnant.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- control group (Type: None): control group receiving regular education from a nurse
- Case management group (Type: None): This is the study group. Extensive education and case management program will be performed in this group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete